Pantoprazol Protect Stada (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Protect Stada, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults. GNH USA supplies Pantoprazol Protect Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Protect Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Protect Stada is a proton pump inhibitor that addresses acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Peptic ulcer disease: supports ulcer healing and prevents relapse. - Helicobacter pylori eradication regimens: used as an adjunct to antibiotic therapy to improve eradication rates.

Pantoprazol Protect Stada may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, often transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea, fever, abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat, seizures. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatitis such as jaundice or dark urine. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output and swelling.

Before starting Pantoprazol Protect Stada, consider the following safety measures:

- Assess renal function: adjust use in severe kidney impairment. - Evaluate liver health: use with caution in hepatic disease. - Review long‑term therapy: monitor for bone density loss with extended use. - Pregnancy and lactation: discuss risks and benefits with a healthcare professional. - Concomitant medications: check for potential drug‑drug interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Protect Stada can affect the absorption or metabolism of several medicines. Careful management is recommended.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption leading to therapeutic failure. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values, requiring more frequent monitoring. - Digoxin: possible increase in serum levels. - Methotrexate: reduced renal clearance may raise toxicity risk. - Oral contraceptives: slight decrease in efficacy, advise backup contraception.